Balancing act

Medication combo reduces repeat MI but carries other risks

issue 24 | Summer 2015

Long-term use of ticagrelor with aspirin after myocardial infarction (MI) significantly reduced the risk of a recurrence, stroke or cardiovascular death, but increased major bleeding risk, according to findings from the PEGASUS trial.

The University of Michigan Frankel Cardiovascular Center was one of 1,161 sites in the international study. Patients randomized one to three years after an MI to a median 33 months of dual antiplatelet therapy with ticagrelor cut those risks compared with a similar duration of aspirin alone. The trial results were presented at the American College of Cardiology meeting and published simultaneously in the New England Journal of Medicine. Nearly 8 million people in the U.S. have a history of MI.